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AbsTRACT 
background Pneumococcal conjugate vaccines (PcVs) 
have the potential to prevent pneumococcal disease 
through direct and indirect protection. this multicentre 
european study estimated the indirect effects of 5-year 
childhood PcV10 and/or PcV13 programmes on invasive 
pneumococcal disease (iPD) in older adults across 13 sites 
in 10 european countries, to support decision-making on 
pneumococcal vaccination policies.
Methods For each site we calculated iPD incidence rate 
ratios (irr) in people aged ≥65 years by serotype for each 
PcV10/13 year (2011–2015) compared with 2009 (pre-
PcV10/13). We calculated pooled irr and 95% ci using 
random-effects meta-analysis and PcV10/13 effect as (1 
− irr)*100.
Results after five PcV10/13 years, the incidence of iPD 
caused by all types, PcV7 and additional PcV13 serotypes 
declined 9% (95% ci −4% to 19%), 77% (95% ci 67% 
to 84%) and 38% (95% ci 19% to 53%), respectively, 
while the incidence of non-PcV13 serotypes increased 63% 
(95% ci 39% to 91%). the incidence of serotypes included 
in PcV13 and not in PcV10 decreased 37% (95% ci 22% 
to 50%) in six PcV13 sites and increased by 50% (95% 
ci −8% to 146%) in the four sites using PcV10 (alone 
or with PcV13). in 2015, PcV13 serotypes represented 
20–29% and 32–53% of iPD cases in PcV13 and PcV10 
sites, respectively.
Conclusion Overall iPD incidence in older adults decreased 
moderately after five childhood PcV10/13 years in 13 
european sites. large declines in PcV10/13 serotype iPD, 
due to the indirect effect of childhood vaccination, were 
countered by increases in non-PcV13 iPD, but these declines 
varied according to the childhood vaccine used. Decision-
making on pneumococcal vaccination for older adults must 
consider the indirect effects of childhood PcV programmes. 
Sustained monitoring of iPD epidemiology is imperative.
InTRoduCTIon
Streptococcus pneumoniae is associated with signif-
icant morbidity and mortality in older adults. The 
most severe form, invasive pneumococcal disease 
(IPD), includes bacteraemic pneumonia, meningitis 
and septicaemia.1 2 In recent European studies the 
annual incidence of IPD in persons aged ≥65 years 
ranged from 10 to 70 per 100 000.1–5 Pneumo-
coccal conjugate vaccines covering 10 (PCV10) 
and 13 (PCV13) serotypes (table 1) have progres-
sively replaced the 7-valent vaccine (PCV7) in the 
childhood vaccination schedule of most European 
countries during 2010 or 2011. PCV vaccination 
policies are heterogeneous between countries. In 
2014, among 17 Western European countries, eight 
used PCV13 only, four used PCV10 only and five 
used both vaccines in the childhood vaccination 
programme.6 PCV13 has also been approved in 
Key messages
What is the key question?
 ► This study assesses the indirect effect of 5 years 
of childhood PCV10 and/or PCV13 programmes 
on invasive pneumococcal disease (IPD) in older 
adults across 10 European countries, using the 
same methodology.
What is the bottom line?
 ► Previous studies in single countries and using 
different methodologies showed diverging 
results in terms of overall benefit (IPD 
incidence) and serotype replacement disease.
Why read on?
 ► Our study reveals that the effect on IPD in 
older adults differs according to the PCV used 
in the childhood programme and highlights 
the continuing rise in non-PCV13 serotypes; 
these findings are important when deciding 
on pneumococcal vaccination policy for 
older adults.
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Table 1 Serotype categories causing invasive pneumococcal disease 
according to the serotype content of vaccines
Category of serotypes serotypes
PCV7 4, 6B, 9V, 14, 18C, 19F and 23F
PCV13non7 (in PCV13 and not in PCV7) 1, 3, 5, 6A 7F and 19A
  PCV10non7 (in PCV10 and not in PCV7) 1, 5 and 7F
  PCV13non10 (in PCV13 and not in PCV10) 3, 6A and 19A
Non-PCV13 (any not in PCV13) Any serotype not in PCV13
PPV23non13 (in PPV23 and not in PCV13) 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 
22F and 33F
Non-vaccine (not in PCV13 nor in PPV23) Any serotype not in PCV13 and not 
in PPV23
Table 2 Vaccination programme, population size, proportion of invasive pneumococcal disease (IPD) cases serotyped and number of IPD cases per 
year among older adults aged ≥65 years by site: SpIDnet/I-MOVE+ multicentre study
sites
Vaccine used (uptake) in 2015
Population 
aged ≥65 years
% typed 
cases†† Adjusted number of cases* per year
In infants In elderly (any) 2015 2015 2009 2010 2011 2012 2013 2014 2015
CZ U, PCV10/PCV13 (71%)† PPV23 (NA) 1 932 412 93% 151 139 134 142 183 157 191
DK U, PCV13 (94%) PPV23 (11%), PCV13 (3%) 1 072 422 94% 569 539 540 544 475 483 560
EW U, PCV13 (94%) PPV23 (70%) 11 000 000 96% 2380 2378 2158 2189 2138 2187 2739
FI U, PCV10 (94%) Risk groups (PPV23 <5%) 1 123 103 99% 295 304 297 342 319 355 427
FR U, PCV13 (94%) Risk groups (PPV23 8%) 9 209 601 NA‡ 2539 2410 2396 2258 1881 1640 1820
IE U, PCV13 (93%) PPV23 (36%)§; PCV13 risk groups¶ 606 011 88% 156 147 160 177 171 168 189
NL U, PCV10 (94%) Risk groups 751 921 100% 331 303 334 360 377 313 402
NO U, PCV13 (93%) PPV23 (15%) 834 302 99% 381 390 381 327 307 311 312
SC U, PCV13 (97%) PPV23 (69%) 982 998 89% 219 255 218 238 285 221 313
SE U, PCV10/PCV13 (97%)† Risk groups 1 912 884 95% 866 819 743 832 789 747 787
CAT PCV10/PCV13 (78%) PPV23 (60%) 1 361 617 90% 490 456 344 413 451 388 449
MAD PCV10/PCV13 (77%)§ PPV23 (60%) 1 079 912 91% 192 174 184 190 183 238 254
NAV (PCV10) PCV13 (81%)** PPV23 (57%) 121 236 90% 30 22 33 34 26 25 30
All NR NR 31 988 419 95% 8599 8336 7922 8046 7585 7233 8473
*Adjusted for the sensitivity of the surveillance system.
†PCV10 and PCV13 are used in similar proportions in those sites.
‡Not computed as two different datasets are used (no case reconciliation).
§2013.
¶ Starting August 2015.
**PCV13 was used almost exclusively as the PCV10 uptake in children aged <2 years has been <1% since 2012.
††The number of serotyped cases divided by all reported cases in that site in 2015.
CAT, Catalonia; CZ, Czech Republic; DK, Denmark; EW, England & Wales; FI, Finland; FR, France; IE, Ireland; MAD, Madrid; NAV, Navarra; NL, the Netherlands; NOR, Norway; NA, 
not available; NR, not relevant; SC, Scotland; SE, Sweden; U, universal programme.
adults for the prevention of IPD since 2011 and in 2015 the 
indication was extended to pneumococcal pneumonia.7
Childhood PCV vaccination may have an indirect effect on 
unvaccinated population groups, especially on older adults (in 
whom the incidence of IPD is very high), through a reduction 
in carriage of vaccine serotypes in vaccinated children, with 
subsequent reduction in circulation and transmission across 
all age groups. However, this indirect effect is also responsible 
for an increase in non-PCV serotypes, called serotype replace-
ment. Indeed, after the introduction of PCV7, the decline 
in PCV7 serotype IPD was partly countered by replacement 
with non-PCV7 serotypes. A few countries have also recently 
reported an indirect effect in adults aged ≥65 years 3–4 years 
after PCV10/13 replaced PCV7 in the childhood vaccination 
programme.8–12 The decrease in overall IPD incidence after 
each PCV introduction is generally limited (<25%) because of 
serotype replacement disease, but its extent is unclear because of 
large confidence intervals.8–12
Some countries with established childhood PCV10/13 
programmes are currently considering whether to introduce 
PCV13 vaccination in elderly people. A key question, there-
fore, is what additional value such a programme might offer 
over the indirect effect of a childhood PCV10/13 programme. 
In older adults, the polysaccharide 23-valent vaccine (PPV23) 
aims to protect against 12 PCV13 serotypes and 11 additional 
non-PCV13 serotypes, but its effectiveness against pneumo-
coccal disease in this age group remains controversial.13 14
SpIDnet and I-MOVE+ are complementary European multi-
centre surveillance projects funded by the European Centre 
for Disease Prevention and Control (ECDC) and the European 
Commission since 2012 and 2015, respectively, to monitor 
the impact and effectiveness of PCV programmes in Europe. 
In 2015, SpIDnet and I-MOVE+ collected IPD data in adults 
from 13 sites across 10 countries: the Czech Republic, Denmark, 
England and Wales, Finland, France, Ireland, the Netherlands, 
Norway, Scotland, Sweden and the Madrid, Catalonia and 
Navarre regions of Spain. PCV7 was introduced in the childhood 
vaccination schedule (2001–2009) across all sites except Finland 
and replaced in 2010–2011 with either universal PCV13 (six 
sites), universal PCV10 (two sites) or both PCV10 and PCV13 
(five sites, two with universal and three with non-universal 
PCV10/13), without catch-up vaccination. At the time of this 
study (2016), none of the sites routinely recommended PCV13 
for all older adults. Nine sites recommended PPV23 for this age 
group; PPV23 uptake varied between 15% and 70% (table 2). 
Five sites recommended PCV13 for at-risk groups, together with 
PPV23.
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We estimated the indirect effect of the childhood PCV10/13 
programme on IPD in adults aged ≥65 years (herein referred 
to as ‘older adults’) across these 13 sites during the first 5 years 
of PCV10/13 use, in order to support decision-making on the 
pneumococcal vaccine policy for older adults across Europe.
MeThods
IPd surveillance systems and data sources
The 13 study sites conduct population-based IPD surveillance, 
with laboratory confirmation and serotyping of invasive pneu-
mococcal isolates from cases residing in the catchment area. 
In 2015, reporting of IPD cases was mandatory in 11 sites and 
voluntary in two sites. IPD cases were defined according to the 
2012 ECDC case definition.15 Aggregated data were collected 
from each surveillance site by calendar year and serotypes. 
All cases identified through surveillance were included in the 
analysis.
The reference laboratories at the respective surveillance sites 
used capsular reaction with specific antisera (Quellung reaction) 
or PCR for serotyping. Serotypes 6A and 6C were differentiated 
by PCR, Quellung or latex agglutination with specific antisera 
at all sites. The national reference laboratories participated in 
the external quality schemes organised by the ECDC during 
2010–2014. Serotypes causing IPD were classified into catego-
ries according to the serotype content of vaccines (see table 1).
Analysis of data
We measured the indirect effect of the childhood PCV10/13 
vaccination programme in older adults by comparing the inci-
dence rate in this age group within a population with an estab-
lished childhood PCV10/13 programme with the incidence rate 
in the same age group in the pre-PCV10/13 period.16 17 The 
pre-vaccine period represents the reference population (without 
a routine PCV10/13 programme) at each site.
For each site we accounted for missing serotype data by 
assuming the same serotype distribution in cases with and 
without serotype information, by calendar year. For three 
sites that reported a change in surveillance sensitivity over the 
surveillance period, we adjusted the number of reported cases 
to the sensitivity for each period, as described elsewhere.18–20 
We computed annual incidence rates per site and serotype by 
dividing the numbers of cases adjusted for missing serotyping 
data and under-reporting by the respective source population.
For each site we thus compared the incidence of IPD in 
people aged ≥65 years before and after the introduction of 
childhood PCV10/13. We calculated site-specific incidence 
rate ratios (IRR) between 2009 and each of the PCV10/13 years 
(2011–2015) by serotype category. As data availability and the 
number of years after PCV7 introduction varied across sites in 
the pre-PCV10/13 period, we selected 2009 as the pre-vaccina-
tion period because it was the last pre-PCV10/13 year common 
to all sites. We performed sensitivity analysis using the average 
incidence during the PCV7 years as the pre-PCV10/13 period 
(and 2005–2008 for Finland). We considered 2010 as a tran-
sition year because PCV13/10 became available shortly before 
or during that year.
We computed pooled IRR and 95% CI by serotype category and 
year using random effects meta-analysis, as we assumed that the 
true indirect effect could vary across sites.21 We also performed 
pooled analyses stratified by the childhood vaccine used. We 
assessed statistical heterogeneity by estimating the between-
study variance using tau-squared (τ²), which is less dependent 
on the number of sites and the precision of site estimates than 
other heterogeneity measures.22 Heterogeneity between studies 
was considered to be low if τ² <0.2, fairly reasonable for τ² 
between 0.2 and 0.5 and fairly high for τ² >0.5 and <1.0.23 
The indirect effect of PCV on IPD in older adults was expressed 
as the percentage change in incidence ((1 − IRR)*100). Statis-
tical analyses were performed using STATA 12.0 (StataCorp, 
Texas, USA).
ResulTs
In 2015 the 13 sites covered around 32 million adults aged ≥65 
years (table 2). PCV uptake in the infant programme exceeded 
93% in 9/10 sites with universal vaccination, and ranged 
between 77% and 81% in the three sites with non-universal 
vaccination. A total of 56 194 IPD cases were reported among 
people aged ≥65 years during 2009–2015. Overall, serotyping 
was performed for 92% of the invasive pneumococcal isolates, 
excluding France where the incidence and serotype distribu-
tion are reported through two different systems without case 
reconciliation as described elsewhere,19 and the serotyping rate 
cannot be calculated. The serotyping rate ranged from 91% to 
95% annually (for all sites) and from 88% to 100% across the 
sites (for all years).
Change in IPd incidence
In the pre-PCV10/13 period the overall IPD incidence rates 
varied by site (figure 1), with higher rates in the Nordic countries 
and the Netherlands. Based on point estimates, IPD incidence 
rates decreased from 2009 to 2014 in 11/13 sites and increased 
from 2014 to 2015 in 12/13 sites (95% CI around IRR including 
1 in 7/12 sites), exceeding the 2009 rates in 4/13 sites (95% CI 
around IRR including 1 in two sites, figure 2A). Pooled anal-
ysis estimated an overall decline of 9% (95% CI −4% to 19%) 
in IPD incidence in 2015 compared with 2009 (pre-PCV10/13 
period, figure 3A, table 3).
The point estimate incidence of PCV7 serotype IPD declined 
across all sites except one (figure 2B). The pooled analysis 
indicated a progressive decline in incidence reaching 77% 
(95% CI 67% to 84%) in 2015 compared with 2009 (figure 3A, 
table 3). PCV13non7 serotype IPD incidence declined in 
11/13 sites over the same period, with a pooled estimate 
decline of 38% (95% CI 19% to 53%) in 2015 (figure 3A, 
table 3). PCV10non7 serotype IPD incidence decreased across 
all sites (figure 2C), reaching 73% (95% CI 59% to –82%) 
decline by 2015 in the pooled analysis (figure 3B, table 3). 
Changes in PCV13non10 serotype IPD incidence varied by 
site; site-specific IRR ranged between 0.4 and 2.9 in 2015 
compared with 2009 (figure 2D). The pooled analysis showed 
a decline in PCV13non10 serotype IPD incidence up to 2014 
followed by an increase in 2015 (figure 3B) based on point 
estimates, although with overlapping 95% CI around the IRR. 
The pooled IRR for serotype 3 IPD fluctuated around 1 during 
the PCV10/13 period (figure 3B, table 3). The incidence of 
IPD due to serotype 19A declined over time but with wide 
confidence intervals (figure 3B, table 3). When the average 
PCV7 period was used as the pre-vaccine period instead of 
the 2009 year, similar patterns were observed with a decline of 
11% (95% CI 0% to 21%) in overall IPD, 83% (95% CI 73% 
to 89%) in PCV7 serotypes and 33% (95% CI 11% to 50%) 
in PCV13non7 serotype IPD incidence by 2015.
The point estimate incidence of non-PCV13 serotype IPD 
increased in 12/13 sites over the PCV10/13 period (figure 2E), 
with a pooled increase of 63% (95% CI 39% to 92%) in 2015 
(figure 3A). Pooled IRR was similar for the 11 non-PCV13 
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Figure 1 Overall incidence of invasive pneumococcal disease per site and years in persons aged ≥65 years over the period 2000–2015: SpIDnet/I-
MOVE+ multicentre study.
serotypes included in PPV23 (PPV23non13) (IRR 1.53, 
1.39–1.68) and the non-vaccine serotypes (1.78, 1.41–2.24; 
figure 3C).
Changes in incidence according to childhood vaccination
We compared pooled IRR for six sites with universal PCV13 
with those of four sites with universal PCV10, used exclu-
sively (two sites) or in similar proportion with PCV13 (two 
sites) (figure 4). From 2009 to 2015, the overall IPD incidence 
declined by 14% in PCV13 sites (95% CI −4% to 30%) and 
by 1% (−21% to 18%) in PCV10 sites. IPD due to PCV7 
and PCV10non7 serotypes decreased in both groups, by 85% 
(95% CI 82% to 88%) and 77% (95% CI 60% to 86%) in 
PCV13 sites and by 78% (95% CI 57% to 89%) and 53% 
(95% CI 24% to 71%) in the sites using PCV10, respec-
tively. IPD due to PCV13non10 serotypes decreased by 37% 
(95% CI 22% to 49%) in PCV13 sites and increased by 50% 
(95% CI −8% to 146%) in the sites using PCV10. Overall, 
PCV13non7 serotype IPD declined by 51% (95% CI 39% to 
61%) in PCV13 sites and increased by 19% (95% CI −26% to 
90%) in PCV10 sites, although with overlapping 95% CI. The 
incidence of IPD due to serotype 19A decreased by 47% (95% 
CI 38% to 61%) in PCV13 sites and increased by 174% (95% 
CI 51% to 399%) in PCV10 sites, with the largest increases 
seen in 2015. The incidence of serotype 3 IPD fluctuated in 
both groups, but decreased in the first 4 years among PCV13 
sites and tended to increase in PCV10 sites. Non-PCV13 type 
IPD showed similar trends in both groups.
serotype distribution among IPd cases in older adults during 
2015
In 2015, PCV7 serotypes represented <20% of all IPD cases 
in older adults at each site (figure 5), with a range of 2–4% 
in PCV13 sites, 6–16% in sites using PCV10 and 10–19% in 
the four sites with limited PCV7 vaccination (none or median 
uptake ≤60%) before the introduction of PCV10/13 (i.e. Cata-
lunya, Navarra, Czech Republic and Finland). Note that Madrid 
had universal PCV7 vaccination between 2007 and 2010 (vaccine 
uptake >90%), replaced by universal PCV13 vaccination up to 
May 2012. PCV10non7 serotypes were responsible for ≤5% of 
IPD cases in all sites except one. PCV13non10 serotypes caused 
11–23% of IPD cases in PCV13 sites and 20–36% in PCV10 
sites. Altogether, PCV13 serotypes represented 20–29% of 
IPD cases in PCV13 sites and 32–53% in sites using PCV10. 
The PPV23non13 serotypes were responsible for 37–54% and 
22–46% of IPD cases in PCV13 and PCV10 sites, respectively.
heterogeneity testing
Based on τ², heterogeneity between studies was low or fairly 
reasonable in all pooled analyses (τ²<0.5), except for serotype 
19A across all sites (τ²=0.5 in 2015). Heterogeneity was low 
(τ²<0.2) in 90% of analyses by vaccine policy and fairly reason-
able (τ²=0.2–0.5) in the remaining 10%.
dIsCussIon
Our pooled analysis of 13 sites from 10 European countries iden-
tified a large indirect effect of childhood PCV programmes on 
IPD among older adults, with IPD caused by PCV7 and PCV10 
serotypes declining by more than 70% after five PCV10/13 years 
compared with the pre-PCV10/13 period. The three serotypes 
included in PCV13 and not in PCV10 declined moderately 
(20%), but the trends differed by site according to whether the 
childhood vaccination programme included PCV10 or PCV13 in 
individual sites. The incidence of IPD due to non-PCV13 sero-
types increased by 63%, restricting the overall changes in IPD 
incidence to a 9% decline, although with wide confidence inter-
vals, after 5 years of the childhood PCV10/13 programme.
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Figure 2 Site incidence rate ratio by serotype category in 2015 compared with 2009: SpIDnet/I-MOVE+ multicentre study. (A) All. (B) PCV7. (C) 
Included in PCV10 and not in PCV7 (1, 5 and 7F). (D) Included in PCV13 and not in PCV10 (3, 6A and 19A). (E) Non-PCV13. (F) PPV23 non-PCV13. 
(G) Non-vaccine.
The year-on-year increase in the incidence of non-PCV13 
serotypes  during the five PCV10/13 years, suggesting sero-
type replacement in disease, is consistent with recent European 
reports from other sites during at least four PCV10/13 years 
and counters the marked declines in vaccine serotype IPD inci-
dence, thereby restricting the overall benefits of the childhood 
programme on IPD in older adults. In Italy and Germany the 
incidence or number of reported cases in adults aged ≥65 years 
tended to increase over the PCV13 period.24 25 In contrast, in 
the USA the incidence of non-PCV13 IPD did not increase in 
older adults after 3 years of the childhood PCV13 programme.12 
Differences in surveillance methodologies, case definitions and 
clinical practices, as noted since the PCV7 era, along with the 
shorter surveillance interval in the US study may at least partly 
explain this difference.26 27
The incidence of PCV7 serotype IPD declined substantially. 
By 2015 these serotypes represented <5% of IPD cases among 
the older adults in sites where universal PCV13 replaced PCV7 
vaccination. In countries with no or limited PCV7 use prior to 
PCV13 introduction, however, PCV7 serotypes accounted for 
10–19% of IPD cases among the older adults in 2015.
We identified important differences in indirect effects 
according to the PCV used in the childhood programme. After 
5 years the point estimate decline in overall IPD among older 
adults was greater in the six sites with universal PCV13 vacci-
nation compared with the four sites with universal PCV10, 
used exclusively or in equal proportions with PCV13, although 
with wide confidence intervals. This difference was partly 
due to PCV13non10 serotypes, which decreased by 37% in 
PCV13 sites compared with a 50% increase (with wide confi-
dence intervals) in sites using PCV10. This was driven primarily 
by diverging trends in the incidence of serotype 19A IPD and 
could be expected as PCV10 does not contain serotype 19A. IPD 
incidence due to this serotype also increased rapidly in countries 
with established PCV7 programmes prior to PCV13 implemen-
tation. Although a decline in serotype 19A IPD incidence has 
been observed in vaccinated children with PCV10,28 29 poten-
tially through cross-protection from antibodies against serotype 
477Hanquet G, et al. Thorax 2019;74:473–482. doi:10.1136/thoraxjnl-2018-211767
 o
n
 6 June 2019 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2018-211767 on 24 October 2018. Downloaded from 
Respiratory epidemiology
Figure 3 Pooled incidence rate ratio per serotype group over the PCV10/13 years (2011–2015) compared with 2009: SpIDnet/I-MOVE+ multicentre 
study.
19F, this may not be sufficient to offer indirect (herd) protection 
for serotype 19A IPD among older unvaccinated individuals.30 
Similar differences were observed in Sweden between counties 
vaccinating with PCV10 and those vaccinating with PCV13.5 For 
serotype 3, the pooled IRR was <1 in PCV13 sites and >1 in 
PCV10 in 2012–2015, but confidence intervals were too large 
to allow any conclusive interpretation. Although the incidence 
of serotype 3 IPD declined in PCV13 sites in the first 4 years 
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Table 3 Incidence rate ratio of invasive pneumococcal disease (IPD) per PCV10/13 year compared with 2009, 13 sites: SpIDnet/I-
MOVE+ multicentre study
serotypes (group) 2011 (year 1) 2012 (year 2) 2013 (year 3) 2014 (year 4) 2015 (year 5)
All types 0.88 (0.84–0.93) 0.88 (0.85–0.92) 0.86 (0.79–0.93) 0.80 (0.72–0.89) 0.91 (0.81–1.03)
PCV7 0.50 (0.42–0.60) 0.40 (0.30–0.51) 0.32 (0.23–0.44) 0.25 (0.18–0.36) 0.23 (0.16–0.33)
PCV13non7* 0.91 (0.82–1.02) 0.81 (0.72–0.92) 0.72 (0.60–0.86) 0.60 (0.46–0.77) 0.62 (0.47–0.81)
  PCV10non7† 0.87 (0.72–1.05) 0.79 (0.66–0.94) 0.56 (0.43–0.72) 0.44 (0.32–0.61) 0.27 (0.18–0.41)
  PCV13non10‡ 0.95 (0.85–1.05) 0.83 (0.73–0.94) 0.81 (0.65–0.99) 0.68 (0.53–0.87) 0.81 (0.62–1.05)
   Serotype 3 0.93 (0.80–1.08) 0.90 (0.78–1.06) 0.98 (0.79–1.22) 0.89 (0.69–1.16) 1.03 (0.81–1.31)
   Serotype 19A 1.13 (0.95–1.34) 1.06 (0.82–1.37) 0.98 (0.69–1.38) 0.77 (0.56–1.06) 0.87 (0.56–1.06)
NonPCV13 1.10 (1.02–1.19) 1.28 (1.16–1.42) 1.35 (1.17–1.56) 1.35 (1.17–1.57) 1.63 (1.39–1.92)
  PPV23 nonPCV13§ 1.09 (0.91–1.30) 1.19 (1.05–1.36) 1.23 (1.11–1.37) 1.23 (1.12–1.36) 1.53 (1.39–1.68)
  Non-vaccine¶ 1.15 (0.96–1.39) 1.47 (1.23–1.75) 1.54 (1.25–1.91) 1.52 (1.20–1.91) 1.78 (1.41–2.24)
*Serotypes 1, 3, 5, 6A, 7F and 19A.
†Serotypes 1, 5 and 7F.
‡Serotypes 3, 6A and 19A.
§Serotypes 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F.
¶Serotypes not in PPV23 and not in PCV13.
after PCV13 introduction, its increase in 2015 is difficult to 
explain, thus precluding any conclusion about the ability of the 
childhood PCV13 programmes to generate herd effects against 
this serotype. The increase in PCV13non10 serotypes in the four 
PCV10 sites is problematic because serotypes 3 and 19A already 
rank among the most prevalent causes of invasive and non-inva-
sive pneumococcal disease among older adults.2 11
Currently, a major question is whether a PCV13 programme 
for older adults would present an added value compared with 
the indirect effect of the childhood PCV10/13 programme. 
The continuing decline in PCV10/13 serotype IPD in older 
adults through the indirect benefits of the childhood PCV10/13 
programme in this study, as in other European studies,10 23 25 31 32 
is one factor which explains why most European countries do not 
advise routine PCV13 for older adults. Our study is, however, 
the first multi-country study to estimate residual PCV13 disease 
and differing trends depending on the country’s childhood PCV 
policy. In PCV13 sites, PCV13 serotypes represented <30% 
of all IPD among older adults in 2015 and the incidence of 
PCV13non7 serotype IPD halved after five PCV13 years. In 
contrast, in the PCV10 sites, PCV13 serotypes were respon-
sible for one-third to one-half of IPD cases among older adults 
in 2015 and the incidence of PCV13non7 serotype IPD tended 
to increase over the five PCV10 years. Although future trends 
cannot be predicted, our results suggest that, in countries using 
PCV10 in the childhood schedule, a higher proportion of IPD 
cases would be targeted by a PCV13 programme for older 
adults. This group, however, comprises more than 30 1-year age 
cohorts and such a programme would only offer direct protec-
tion to vaccinated older adults.
The incidence of PPV23non13 serotypes rose by 50% after 
5 years of the childhood PCV10/13 programme and will most 
likely continue to increase with more years of PCV10/13 use; 
these 11 serotypes were responsible for 22–54% of IPD among 
older adults per site in 2015. A recent meta-analysis assessing 
indirect PCV effects reported a smaller increase in PPV23non13 
serotypes in older adults (IRR 1.18 (1.12–1.25)), but the anal-
ysis mixed data across different continents, with variable 
pre-vaccine and post-PCV10/13 periods.23 We did not take into 
account PPV23 use which is recommended for older adults in 
some countries. As our study period does not cover the years 
before PPV23 introduction, this could bias our estimates only if 
PPV23 uptake varied during the study period, which was not the 
case. Moreover, we did not identify any different trends among 
PPV23non13 serotypes by PPV23 use, as the sites with the 
highest uptake (England and Wales, and Scotland, ~70%) had 
similar IRR to the pooled estimate (1.46 and 1.60, respectively, 
compared with 1.50).
In 2015 the overall IPD incidence in older adults increased in 
12/13 sites compared with 2014 (although 95% CI overlapped 
in 7/12 sites), almost entirely due to non-PCV13 serotypes. The 
exception was Norway, but preliminary data suggest that the IPD 
incidence increased by 18% between 2015 and 2016 because 
of an increase in IPD due to non-PCV13 serotypes; prelimi-
nary data from some sites indicate a further rise in 2016, again 
due to non-PCV13 serotypes.5 33 34 Monitoring IPD serotype 
trends across all age groups in countries with ongoing childhood 
PCV10/13 programmes is therefore essential.
The reasons for higher pre-vaccine incidence rates in four 
countries (the Nordic countries and the Netherlands) were not 
explored in our study. No difference in surveillance sensitivity 
was identified in these sites, but substantial increases in overall 
IPD incidence prior to PCV7 introduction (1995–2004) were 
reported in older adults in these four countries, mostly due to 
rises in serotypes 1, 4 and 14.35–39 In other sites with longer 
pre-PCV7 data in our study, such as the UK and France, IPD inci-
dence rates were stable (figure 1). We hypothesise that regional 
circulation of specific serotypes or pneumococcal clones caused 
these higher incidences, although differences in social contact 
patterns and case detection cannot be excluded.
Our results cannot be easily compared with studies from 
other sites, which were usually restricted to single sites, included 
shorter post-PCV13 periods (2–3 years) or used an average inci-
dence over the post-vaccine period.12 23 25 40 The added value of 
our study is the pooling of 13 sites from 10 European countries, 
coverage of five PCV10/13 years and IRR estimations for each 
PCV10/13 year. There are, however, some limitations. First, 
methodologies comparing pre- and post-vaccination incidences 
are prone to biases, whereby changes in other factors over time 
such as case detection (eg, blood culturing frequency), reporting 
and other health interventions may be attributed to the vacci-
nation programme. We partly addressed that risk by adjusting 
for surveillance sensitivity whenever possible. Although we 
cannot exclude biases due to changes in IPD case detection 
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Figure 4 Pooled incidence rate ratio per serotype group over the PCV10/13 years compared with 2009 by vaccine policy: SpIDnet/I-
MOVE+ multicentre study.
and surveillance, these tend to improve in post-vaccine periods 
and would underestimate the vaccine effects.17 19 41 Second, we 
expect heterogeneity across sites due to differences in healthcare 
practices, pre-vaccine epidemiology and vaccination policies. We 
attempted to address this by using random effects meta-analysis 
and performing stratified analysis by PCV policy. We assumed 
that these differences across sites would be constant over time, 
limiting their influence on relative measures of effect such as 
the IRR. Reassuringly, the τ² values suggest limited statistical 
heterogeneity. Third, the selected pre-PCV10/13 reference 
period may influence effect estimates. We selected 2009 as 
the last year before PCV10/13 introduction for all sites, but a 
single year may be more prone to natural fluctuations. Using 
the average annual incidence after PCV7 introduction, however, 
we observed similar patterns in IRR, but with slightly differing 
values, likely reflecting some additional PCV7 effect on PCV7 
and non-PCV7 serotypes in sites with longer periods of PCV7 
included in the analysis. We therefore believe that using 2009 as 
reference provides a more accurate estimate of changes due to 
PCV10/13 only. Finally, given the variability in pneumococcal 
serotype epidemiology and PCV history across the participating 
sites, we cannot infer our findings to the rest of Europe.
ConClusIon
We report the indirect effect of 5 years of the childhood 
PCV10/13 programme on the incidence of IPD in older adults 
across 13 sites in 10 European countries. The large decline in 
IPD due to vaccine serotypes was partly countered by increases 
in non-PCV13 serotypes, resulting in a limited net effect on 
overall IPD. Our findings suggest that the potential benefit of a 
PCV13 programme in older adults progressively reduces over 
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Figure 5 Proportion of serotypes out of all invasive pneumococcal disease in 2015 by serotype group, site and vaccination policies: SpIDnet/I-
MOVE+ multicentre study.
time because of the progressive decline in PCV13 serotype IPD 
and the gradual rise in non-PCV13 serotype IPD across that 
age group. The substantial and increasing proportion of IPD 
due to the additional PPV23 serotypes suggests that the advan-
tage of PPV23 over PCV13 in terms of serotypes covered may 
increase over time in older adults. Our data also suggest that 
IPD trends in older adults differ according to the childhood 
PCV used, especially relating to serotype 19A. Policy makers 
need to take into account the indirect impact of childhood 
programmes when considering vaccination programmes for 
older adults in their decision-making process. Our results also 
indicate that vaccines targeting older adults should include 
other (or at least more) serotypes, or provide a wider mecha-
nism of protection against pneumococcal disease than against 
specific capsular serotypes.
The evolution of this indirect effect is difficult to predict. In 
particular, the consistent observation of an increase in IPD in 
2015 across the European sites, the differing trends in serotype 
19A and the rise in non-PCV13 serotypes raise concerns. This 
highlights the need to further monitor IPD serotype trends in 
future years as more infant cohorts receive PCV10/13.
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